Unknown

Dataset Information

0

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.


ABSTRACT: Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response rates to cytotoxic chemotherapy, and an overall adverse prognosis. In this single-center retrospective study, we analyzed the clinicopathologic characteristics and outcomes of 83 patients with TP53-mutated myeloid malignancies treated at Yale Cancer Center between 9/2015 and 5/2019. Complex karyotypes (n = 75; 90%) and therapy-related malignancies (n = 32; 39%) were common. Median overall survival (OS) was 7.6 months. Intensive chemotherapy did not improve OS compared to lower-intensity treatment for AML patients. Patients who underwent allogeneic hematopoietic stem cell transplant (alloHSCT) had a significantly longer median OS, despite relatively limited follow-up. In conclusion, our data confirm the limited efficacy of intensive chemotherapy approaches for TP53-mutated patients with myeloid neoplasms and suggest that a minority of patients achieve long-term survival with alloHSCT.

SUBMITTER: Bewersdorf JP 

PROVIDER: S-EPMC7603787 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8471083 | biostudies-literature
| S-EPMC5217532 | biostudies-literature
| S-EPMC7013259 | biostudies-literature
| S-EPMC7271596 | biostudies-literature
| S-EPMC9627130 | biostudies-literature
| S-EPMC8582962 | biostudies-literature
| S-EPMC8582368 | biostudies-literature
| S-EPMC8507987 | biostudies-literature
| S-EPMC5600909 | biostudies-literature
| S-EPMC9318025 | biostudies-literature